Navigation Links
Bristol-Myers Squibb Announces Dividend
Date:3/4/2008

NEW YORK, March 4 /PRNewswire-FirstCall/ -- The Board of Directors of Bristol-Myers Squibb Company (NYSE: BMY) today declared a quarterly dividend of thirty-one cents ($0.31) per share on the $.10 par value Common Stock of the corporation. The quarterly dividend will be payable on May 1, 2008, to stockholders of record at the close of business on April 4, 2008.

The Directors also declared a quarterly dividend of fifty cents ($0.50) per share on the $2.00 Convertible Preferred Stock of the corporation, payable June 2, 2008, to stockholders of record at the close of business on May 9, 2008.

Bristol-Myers Squibb Company is a global biopharmaceutical and related health care products company whose mission is to extend and enhance human life.


'/>"/>
SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board
2. Bristol-Myers Squibb to Announce Results for the Fourth Quarter and Full Year of 2007 on January 31
3. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
4. EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services
5. Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
6. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
7. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
8. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
9. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
10. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
11. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
(Date:3/22/2017)...  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... address significant unmet medical needs in rare diseases, ... ended December 31, 2016. "2016 ... we broadened our pipeline and pursued our vision ... with an initial focus on endocrinology," said ...
(Date:3/22/2017)... JERUSALEM , March 22, 2017 ... ( www.oramed.com ), ... of oral drug delivery systems, announced today that ... Officer, will deliver a presentation titled, "Oral Insulin ... upcoming Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics ...
(Date:3/22/2017)... Florida , March 22, 2017 ... ... various cancer conditions are being pressured as of late due ... for cancer pain management has a dramatic impact on patient,s ... research and development activities for identifying new forms of opioid ...
Breaking Biology Technology:
(Date:3/2/2017)... 2017 Summary This report provides all ... partnering interests and activities since 2010. ... Read the full report: ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
Breaking Biology News(10 mins):